Cardioprotective Effect of Tanopati against Doxorubicin-induced Myocardial Toxicity in Wistar Rats
Amani Komenan Nazaire *
Department of Biochemistry, Laboratory of Biochemical Pharmacodynamy, Félix Houphouët Boigny University of Abidjan, (225)22 BP 582 Abidjan 22, Côte d’Ivoire.
Kouassi Konan
Department of Biochemistry, Laboratory of Biochemical Pharmacodynamy, Félix Houphouët Boigny University of Abidjan, (225)22 BP 582 Abidjan 22, Côte d’Ivoire.
Konan Kouakou Severin
Department of Biochemistry and Food Sciences, Gbon Peleforo University of Korhogo, (225)22 BP 1328 Korhogo, Côte d’Ivoire.
Yapi Houphouet Felix
Department of Biochemistry, Laboratory of Biochemical Pharmacodynamy, Félix Houphouët Boigny University of Abidjan, (225)22 BP 582 Abidjan 22, Côte d’Ivoire.
Djaman Allico Joseph
Department of Medical and Fundamental Biochemistry, Pasteur Institute of Côte d’Ivoire, (225)01 BP 490 Abidjan 01, Côte d’Ivoire
N’Guessan Jean David
Department of Biochemistry, Laboratory of Biochemical Pharmacodynamy, Félix Houphouët Boigny University of Abidjan, (225)22 BP 582 Abidjan 22, Côte d’Ivoire.
*Author to whom correspondence should be addressed.
Abstract
Aim: The objective of this study was to determine the preventive role of Tanopati against doxorubicin induced myocardial toxicity in rats.
Study Design: Randomized experimental controlled study.
Place and Duration of Study: This study was carried out in Laboratory of Biochemical Pharmacodynamy, Félix Houphouët-Boigny University of Abidjan, Côte d’Ivoire between July 2014 and January 2015.
Methodology: Twenty five albino Wistar rats, divided into five groups with five rats each, were used in this study. Cardiotoxicity was induced by doxorubicin(dox) (15 mg/kg for 2 weeks). Tanopati (10 mg/kg orally) or vitamin E (100 mg/kg orally) was administered as pretreatment for two weeks, and followed by dox for another two weeks. Biomarkers like lactate dehydrogenase (LDH), creatine phosphokinase (CK), iso enzyme CKMB, lipid peroxidation activity, antioxidants such as glutathione (GSH), and antioxidants enzymes such as glutathione (GSH), superoxide dismutase (SOD) and catalase (CAT) levels were monitored 36 hours after administration of the final dose. Histopathological examination was performed.
Results: The repeated administration of dox (2.5 mg/kg of body weight) caused cardiomyopathy associated with an antioxidant deficit. Pretreatment with Tanopati decreased LDH (417.6±1.17 to 324.6±1.7 UI/L), CK (328.2±0.8 to 230.5±1.09 UI/L) and CKMB (234.9±1.03 to 172.2±2.06 UI/L) levels compared to the values in the control group. Tanopati significantly protected the myocardium from the toxic effect of dox, by increasing the levels of antioxidants such as GSH (1.56±0.03 to 1.76±0.02 nmol /g of heart tissue), SOD (21.66±0.34 to 29.93±0.13 U/g of protein), and CAT (40.13±0.65 to 46.57±0.55 µmol H2O2/min/mg of protein) and decreasing the level of malondialdehyde (MDA) (48.09±1.0.83 to 25.46±0.7 nmol/g). Tanopati also reduced the severity of cellular damage of the myocardium as observed microscopically.
Conclusion: The results obtained suggest that cardioprotective effect of Tanopati might be attributed to its antioxidant activity.
Keywords: Tanopati, antioxidant, cardiotoxicity, doxorubicin, free radicals